RSA and Swissbit Announce New Phishing-Resistant Authentication Solution for Security-First Industries
1.10.2024 11:00:00 CEST | Business Wire | Press Release
RSA, the security-first identity leader and Swissbit, a long-standing leading expert and manufacturer of storage, security, and embedded IoT solutions, announced a new, next-generation hardware authenticator series today designed to protect highly regulated industries.
The RSA iShield Key 2 series, powered by Swissbit, will provide financial services, energy, healthcare, and other highly regulated organizations with the highest-level of phishing-resistant, passwordless authentication needed to simplify credential management and drive toward Zero Architecture (ZTA). Optimized for the RSA cloud identity and access management (IAM) platform, RSA® ID Plus, the RSA iShield Key 2 series offers premiere security and unparalleled flexibility. The RSA iShield Key 2 series is available for order now and will ship Q4 2024.
“The worst attacks demand the best defenses. That’s why security-first leaders have trusted RSA for decades to defend them from the most damaging cyberattacks. By working with a leader like Swissbit, we can expand our unified identity platform and deliver innovations like the RSA iShield Key 2 that provide a broader range of capabilities, all fortified by the security depth unique to RSA,” said Rohit Ghai, CEO, RSA.
“To secure their operations and stay operational, leaders in finance, healthcare, energy, and manufacturing need strong, phishing-resistant capabilities built to enable users and resist modern attacks. Together, Swissbit and RSA are bringing those innovations to the private sector organizations that need them most,” said Silvio Muschter, CEO of Swissbit AG.
By offering the RSA iShield Key 2 series through ID Plus, RSA and Swissbit can bring organizations key benefits, including:
- Secure, phishing-resistant authentication: the RSA DS100, RSA Authenticator App, and the RSA iShield Key 2 series supports FIDO2, smart card, and OTP for legacy applications, providing multi-protocol multi-factor authentication (MFA) for a variety of users and use cases.
- FIPS 140-3 validated security: the RSA iShield Key 2 series provides the highest level of cryptographic protection and ensures that every organization’s infrastructure meets the most stringent cybersecurity requirements.
- Accelerating Zero Trust maturity: RSA ID Plus allows organizations to meet key ZTA requirements, including implementing centralized credential management and visibility over all access points.
- Single sign-on (SSO) and self-service capabilities: users can easily register, update, and manage their credentials with RSA ID Plus, minimizing costs on IT teams and accelerating productivity.
Availability and support
The RSA iShield Key 2 series, powered by Swissbit, is available for order now and will ship at the end of 2024. Both companies will support their customers with comprehensive training and support services to ensure smooth integration and implementation.
Resources:
About RSA
The AI-powered RSA Unified Identity Platform protects the world’s most secure organizations from today’s and tomorrow’s highest-risk cyberattacks. RSA provides the identity intelligence, authentication, access, governance, and lifecycle capabilities needed to prevent threats, secure access, and enable compliance. More than 9,000 security-first organizations trust RSA to manage more than 60 million identities across on-premises, hybrid, and multi-cloud environments. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.
About Swissbit
Swissbit AG is the leading European provider of storage, security and embedded IoT solutions for demanding applications. Swissbit combines its unique competencies in storage and embedded IoT technology with its advanced packaging know-how. This expertise allows our customers to reliably store and protect data in industrial, NetCom, automotive, medical and fiscal applications as well as across the Internet of Things (IoT). Swissbit develops and manufactures industrial-grade storage and security products “Made in Germany” with high reliability, long-term availability, and custom optimization. Swissbit was founded in 2001 and has offices in Switzerland, Germany, USA, Japan and Taiwan. For further information, please visit www.swissbit.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001333919/en/
Contacts
Media contact:
teamrsa@axicom.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom